GLP-1 & compounded medication availability in Wyoming (2026)
Wyoming is a mail-order state by geography: with the smallest population in the country and long distances between towns, prescriptions arriving by mail are ordinary here, and the state’s pharmacy rules are built around licensing the pharmacies that do it rather than policing individual medication categories. Below: exactly which of the ten product lines we track ship to Wyoming addresses, and what the state’s pharmacy regulators ask of our partner pharmacies before a single package crosses the state line.
What ships to Wyoming: all ten lines
| Product line | Available in Wyoming? | Typical delivery | Notes |
|---|---|---|---|
| GLP-1 (compounded semaglutide) | Yes | 8–10 business days | Mail-order delivery to every Wyoming address. |
| GLP-1/GIP (compounded tirzepatide) | Yes | 8–10 business days | One national price at each dose. |
| NAD+ | Yes | 8–10 business days | Ordered the same way as our weight-care lines. |
| Sermorelin | Yes | 8–10 business days | Longevity family; ships by mail. |
| Glutathione | No | N/A | Not part of the OrderlyMeds catalog right now. |
| BPC-157 | Yes | 8–10 business days | An injectable in our formulary. Federal record below. |
| TB-500 | Yes | 8–10 business days | In the formulary as an injectable; details below. |
| KPV | No | N/A | Not stocked, because our peptide lines are injectables and KPV is not one. |
| Epitalon | Yes | 8–10 business days | In the formulary as an injectable; its section is below. |
| MOTS-c | Yes | 8–10 business days | An injectable with its own federal record, stated below. |
Every “No” above is deliberate, because an honest catalog beats a padded one. Wyoming facts on this page were last reviewed on November 16, 2026.
Research peptides in Wyoming: BPC-157, TB-500, KPV, Epitalon & MOTS-c
BPC-157, TB-500, Epitalon and MOTS-c are in the OrderlyMeds formulary for Wyoming, compounded as injectables and dispensed on patient-specific prescriptions. KPV is not, because we compound these lines as injectables only. What follows states each substance’s own federal record, available here or not, because a straight answer beats a sales pitch on exactly these questions.
BPC-157 in Wyoming
A Wyoming-available formulary injectable, patient-specific prescription required. Federal record below.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed BPC-157 in Category 2, and BPC-157 has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense BPC-157 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
TB-500 in Wyoming
Ships to Wyoming as a compounded injectable under a patient-specific prescription; read the record below first.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed TB-500 (thymosin beta-4 fragment) in Category 2, and TB-500 (thymosin beta-4 fragment) has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense TB-500 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
KPV in Wyoming
We do not dispense KPV in Wyoming or any state, because these lines are compounded as injectables only.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed KPV in Category 2, and KPV has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense KPV pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
Epitalon in Wyoming
In the Wyoming offering as a compounded injectable on a patient-specific prescription. The federal facts stand regardless.
FDA’s evaluation of bulk drug substances for compounding under section 503A placed Epitalon in Category 2, and Epitalon has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense Epitalon pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).
MOTS-c in Wyoming
Ships to Wyoming as a compounded injectable, on a prescription specific to you. Its federal record is distinct from the four above.
FDA has evaluated MOTS-c as a bulk drug substance nominated for the section 503A bulks list and proposed that neither MOTS-c (free base) nor MOTS-c acetate be included on it, and MOTS-c has no FDA-approved indication. MOTS-c was formerly listed in Category 2 of FDA’s interim compounding policy, and it is no longer on that active list as of FDA’s April 22, 2026 update, because the nomination was withdrawn by the nominator. FDA’s record for the substance notes a potential immunogenicity concern by certain routes and no clinical data in humans, and FDA presented MOTS-c to its Pharmacy Compounding Advisory Committee in July 2026. Under the enforcement-discretion policy HHS published October 30, 2026 at 91 FR 68526, HHS does not intend to act against a state-licensed pharmacy, Federal facility, or licensed physician compounding MOTS-c under section 503A, limited to subcutaneous or intramuscular administration, under a valid patient-specific prescription, and subject to the policy’s other conditions, while rulemaking on the bulks list is pending. That policy does not add MOTS-c to the bulks list and does not make it an FDA-approved drug. Sources: FDA — bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) · FDA — PCAC briefing document, July 23–24, 2026 (MOTS-c proposals, points 7–8) · HHS — 91 FR 68526, enforcement-discretion policy for 503A peptide compounding.
What Wyoming’s pharmacy regulators say about compounded medications
Wyoming keeps its pharmacy oversight compact: one board, one set of Pharmacy Act rules, and a licensing path for every out-of-state pharmacy that mails medications into the state. For a Wyoming patient using telehealth, the operative questions are the same three as anywhere: is the prescriber licensed for Wyoming, is the pharmacy licensed for Wyoming, and is the prescription written for you.
The Wyoming Pharmacy Act Rules carry a dedicated compounding chapter (Chapter 22), with revisions approved and published by the board; no GLP-1-specific or peptide-specific prohibition appears in the board’s published rules. Source: Wyoming State Board of Pharmacy.
A pharmacy located outside Wyoming that ships, mails, or delivers dispensed prescription drugs to a patient in Wyoming must hold a nonresident pharmacy license from the board. Source: Wyoming State Board of Pharmacy — nonresident pharmacy licensing.
Wyoming permits a provider-patient relationship to be established by telemedicine, and non-controlled medications may be prescribed following a real-time telehealth encounter held to the in-person standard of care. Source: CCHP Policy Finder — Wyoming.
From signup to doorstep, a Wyoming order is ordinary by design: eligibility check online, telehealth evaluation by a Wyoming-licensed provider, fulfillment by a licensed nonresident partner pharmacy, delivery by mail. The price is the published national price, and Wyoming pays the same as everyone.
Wyoming availability FAQs
Is compounded semaglutide available in Wyoming?
Yes. It ships by mail to every Wyoming address, at the same national price, starting at $74/month for the first two months.
Do I need to drive to a clinic to get started in Wyoming?
No. The evaluation is a telehealth visit with a provider licensed for Wyoming; the regulator section above carries the cited detail.
Which research peptides ship to Wyoming?
BPC-157, TB-500, Epitalon and MOTS-c, each a compounded injectable on a patient-specific prescription. KPV is not carried in any state. Their federal records are stated line by line above.
How long does delivery to Wyoming take?
8–10 business days from signup is our published window, and it is the same window in every state.
Keep exploring
Ready when you are
See if you’re eligible
Compounded semaglutide from $74/month for your first 2 months — provider visit, medication, syringes, and shipping all included, at the same price for every dose. No membership fees.
Check eligibilitySecure. Private. No commitment
